Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia

Purpose:

RATIONALE: Collecting and storing stem cells to study in the laboratory may help doctors learn more about collecting stem cells from patients who have undergone treatment for Waldenstrom's macroglobulinemia. PURPOSE: This laboratory study is collecting stem cells from patients with Waldenstrom's macroglobulinemia.

Study summary:

OBJECTIVES: - Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's macroglobulinemia (WM) for potential future use in transplantation strategies. - Evaluate the ability to harvest stem cells after therapy for WM (e.g., fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest. - Collect aliquots of stem cells for future research analysis as part of a WM database project. OUTLINE: Patients undergo collection of autologous stem cells beginning on day 4 or 5 and continuing until an adequate number of stem cells are collected. Cells are then cryopreserved. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of Waldenstrom's macroglobulinemia (WM) - Less than 30% lymphoplasmacytoid cells in bone marrow by histopathology - Received prior chemotherapy for WM PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - WBC > 2,000/mm³ - Platelet count > 50,000/mm³ - LVEF ≥ 50% - No organ dysfunction that would preclude future transplantation PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Study is Available At:

Original ID:

CDR0000487602

NCT ID:

NCT00899119

Secondary ID:

CPMC-AAAB4806

Study Acronym:

Brief Title:

Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

Official Title:

Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia

ClinicalTrials.gov Link:

http://clinicaltrials.gov/show/NCT00899119

Overall Status:

Recruiting

Study Phase:

N/A

Genders:

Both

Minimum Age:

18 Years

Maximum Age:

N/A

Study Source:

National Cancer Institute (NCI)

Oversight Authority:

Unspecified

Reasons Why Stopped:

Study Type:

Observational

Study Design:

N/A

Number of Arms:

0

Number of Groups:

0

Total Enrollment:

40

Enrollment Type:

Anticipated

Data Source: ClinicalTrials.gov

Date Processed: February 02, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.